Comparative Pharmacology
Head-to-head clinical analysis: HIPPURAN I 131 versus HIPPUTOPE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HIPPURAN I 131 versus HIPPUTOPE.
HIPPURAN I 131 vs HIPPUTOPE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HIPPURAN I 131 (iodohippurate sodium I-131) is a radiopharmaceutical that is actively transported by the renal tubules, allowing dynamic imaging of renal function. The I-131 isotope emits beta and gamma radiation, enabling scintigraphic visualization of renal perfusion and excretion.
HIPPUTOPE is a diagnostic agent used to assess renal function. It is a radiolabeled compound that undergoes glomerular filtration and tubular secretion, allowing measurement of renal plasma flow and tubular function via imaging.
1 mCi (37 MBq) intravenously for adults; dose adjusted based on clinical indication and imaging protocol.
100-300 microcuries (3.7-11.1 MBq) intravenous, single dose for renal imaging.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged in renal impairment, up to 20-40 hours in severe impairment.
Terminal elimination half-life is 1.5–2.5 hours; prolonged to 6–12 hours in moderate-to-severe renal impairment (CrCl <30 mL/min).
Renal: >95% excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Primarily renal excretion (approximately 90% as unchanged drug via glomerular filtration), with minor biliary/fecal elimination (<10%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical